Corcept Therapeutics News

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

Benzinga01:35

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 127K in Common Stocks

SEC FILLINGS DISCLOSED/ May 9, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on May 9, with a total market value of approximately $127K.

Futu News00:38

Corcept Therapeutics(CORT.US) Officer Sells US$281.58K in Common Stock

$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 10,830 shares of common stock on May 2, 2024 at an average price of $26 for a total value of $281.58K.Source: Announcement What is stat

Futu NewsMay 7 09:03

Corcept Therapeutics(CORT.US) Director Sells US$50,798 in Common Stock

$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of common stock on May 1, 2024 at an average price of $23.09 for a total value of $50,798.Source: Announcement What is st

Futu NewsMay 4 04:49

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $40

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics with a Buy and raises the price target from $38 to $40.

Analyst UpgradesMay 3 01:33

Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities

Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities

Dow JonesMay 2 21:23

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesMay 2 21:23

Earnings Call Summary | Corcept Therapeutics(CORT.US) Q1 2024 Earnings Conference

The following is a summary of the Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript:Financial Performance:Corcept Therapeutics reported Q1 2024 revenues of $146.8 million, a 39

Futu NewsMay 2 21:20 · Conference Call

Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating

Corcept Therapeutics (CORT) has an average rating of buy and price targets ranging from $35 to $61, according to analysts polled by Capital IQ. Price: 26.15, Change: +2.27, Percent Change: +9.51

MT NewswiresMay 2 20:30

Q1 2024 Corcept Therapeutics Inc Earnings Call

Yahoo FinanceMay 2 20:01

Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 2 11:42

Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024

Yahoo FinanceMay 2 05:50

Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.

Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.

BenzingaMay 2 04:32

Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est

Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est

BenzingaMay 2 04:19

Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, Vs. Street Est of $0.22

04:12 PM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22

MT NewswiresMay 2 04:12

Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT

Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT

Dow JonesMay 2 04:08

Corcept Therapeutics 1Q EPS 25c >CORT

Corcept Therapeutics 1Q EPS 25c >CORT

Dow JonesMay 2 04:05

Press Release: Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a c

Dow JonesMay 2 04:05

Corcept Completes Enrollment In Phase 4 CATALYST Trial

Corcept Completes Enrollment In Phase 4 CATALYST Trial

BenzingaApr 29 20:07

20 Companies Screened for Quality in a Cheap -2-

CarGurus Inc. Class A CARG 13.9% 0.0% 28.5% 4.8% 12.0% Inter

MarketWatchApr 27 18:25